E. Rico-Bautista

发表

Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects.

Warren S Alexander, Douglas J Hilton, W. Alexander, 2005, Molecular endocrinology.

Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists.

S. Betz, S. H. Kim, Yun-fei Zhu, 2020, Bioorganic & medicinal chemistry letters.

Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway.

G. Norstedt, A. Flores-Morales, E. Rico-Bautista, 2001, Molecular endocrinology.

Oxidized analogs of Di(1H-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity

John Calvin Reed, M. Andreeff, D. Hansel, 2018, Oncotarget.

SOCS 2 negatively regulates growth hormone action in vitro and in vivo

C. Ohlsson, W. Alexander, D. Hilton, 2005 .

In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver.

B. Lenhard, P. Rotwein, G. Norstedt, 2007, Molecular endocrinology.

Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.

S. Betz, Melissa A. Fowler, E. Sturchler, 2022, Bioorganic & medicinal chemistry letters.

Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via Unfolded Protein Response Signaling

S. Krajewski, J. Bush, S. Ganapathy, 2013, Oncotarget.

SOCS2 negatively regulates growth hormone action in vitro and in vivo.

Claes Ohlsson, Mattias Lorentzon, Donald Metcalf, 2005, The Journal of clinical investigation.

Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions.

A. Flores-Morales, Elizabeth Rico-Bautista, Amilcar Flores-Morales, 2006, Cytokine & growth factor reviews.

Negative regulation of growth hormone receptor signaling.

G. Norstedt, A. Flores-Morales, Christopher J Greenhalgh, 2006, Molecular endocrinology.

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist

S. H. Kim, S. Markison, E. Rico-Bautista, 2022, ACS medicinal chemistry letters.

Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist.

S. Betz, Yun-fei Zhu, E. Rico-Bautista, 2020, Bioorganic & medicinal chemistry letters.

Downregulation of the growth hormone-induced Janus kinase 2/signal transducer and activator of transcription 5 signaling pathway requires an intact actin cytoskeleton.

A. Flores-Morales, L. Fernández-Pérez, E. Rico-Bautista, 2004, Experimental cell research.

SOCS2 deficiency induces molecular and metabolic changes that partially overlap with GH- dependent effects

W. Alexander, D. Hilton, G. Norstedt, 2004 .

Relative impact of 3- and 5-hydroxyl groups of cytosporone B on cancer cell viability.

A. Bobkov, M. Dawson, D. Wolf, 2013, MedChemComm.

Female-predominant expression of fatty acid translocase/CD36 in rat and human liver.

G. Norstedt, R. Fisher, A. Flores-Morales, 2004, Endocrinology.

Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation.

D. Wolf, E. Rico-Bautista, Elizabeth Rico-Bautista, 2012, Chemistry & biology.

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism

P. Arroyo, Diva D. De León, E. Rico-Bautista, 2023, The Journal of biological chemistry.

LBSAT142 Discovery And Characterization Of A Potent And Orally Bioavailable Parathyroid Hormone Receptor Type-1 (PTHR1) Antagonist For The Treatment Of Hypercalcemia

S. Betz, Beth A. Fleck, P. Arroyo, 2022, Journal of the Endocrine Society.

Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells

G. Roth, D. Wolf, E. Rico-Bautista, 2010, BMC Biology.